http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006137349-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate | 2005-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006137349-A |
| titleOfInvention | LONG-TERM COMPOSITIONS BASED ON NALTREXON |
| abstract | 1. A method of treating a person from alcohol dependence, comprising the step of parenterally administering a sustained-release composition containing naltrexone, wherein the serum AUC for naltrexone is at least about two times, preferably at least about three times, more preferably approximately 3.3 times greater than the corresponding value achieved with the introduction of 50 mg / day orally. ! 2. The method according to claim 1, characterized in that the sustained release composition releases naltrexone for at least two weeks. ! 3. The method according to claim 1, characterized in that the sustained release formulation releases naltrexone within about four weeks. ! 4. The method according to claim 1, characterized in that the composition of the prolonged action is administered in a dose equal to at least about 160 mg of naltrexone. ! 5. The method according to claim 1, characterized in that the composition of the prolonged action is administered in a dose equal to about 160-240 mg of naltrexone. ! 6. The method according to claim 5, characterized in that the composition of the prolonged action is administered in a dose equal to about 190 mg of naltrexone. ! 7. The method according to claim 1, characterized in that the composition of the prolonged action is administered in a dose equal to about 310-480 mg of naltrexone. ! 8. The method according to claim 1, characterized in that the composition of the prolonged action is administered in a dose equal to about 380 mg of naltrexone. ! 9. The method according to claim 1, characterized in that the composition of the prolonged action is administered for about 24 weeks or longer. ! 10. The method according to claim 1, characterized in that it further comprises a second administration of a sustained release composition comprising naltrexone after at least about 7 days, preferably |
| priorityDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.